174 related articles for article (PubMed ID: 22351740)
1. Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: a CellSearch analysis.
Gazzaniga P; Gradilone A; de Berardinis E; Busetto GM; Raimondi C; Gandini O; Nicolazzo C; Petracca A; Vincenzi B; Farcomeni A; Gentile V; Cortesi E; Frati L
Ann Oncol; 2012 Sep; 23(9):2352-2356. PubMed ID: 22351740
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumor cells detection has independent prognostic impact in high-risk non-muscle invasive bladder cancer.
Gazzaniga P; de Berardinis E; Raimondi C; Gradilone A; Busetto GM; De Falco E; Nicolazzo C; Giovannone R; Gentile V; Cortesi E; Pantel K
Int J Cancer; 2014 Oct; 135(8):1978-82. PubMed ID: 24599551
[TBL] [Abstract][Full Text] [Related]
3. The Prognostic Role of Circulating Tumor Cells (CTC) in High-risk Non-muscle-invasive Bladder Cancer.
Busetto GM; Ferro M; Del Giudice F; Antonini G; Chung BI; Sperduti I; Giannarelli D; Lucarelli G; Borghesi M; Musi G; de Cobelli O; De Berardinis E
Clin Genitourin Cancer; 2017 Aug; 15(4):e661-e666. PubMed ID: 28188046
[TBL] [Abstract][Full Text] [Related]
4. Characterization of Urothelial Cancer Circulating Tumor Cells with a Novel Selection-Free Method.
Chalfin HJ; Kates M; van der Toom EE; Glavaris S; Verdone JE; Hahn NM; Pienta KJ; Bivalacqua TJ; Gorin MA
Urology; 2018 May; 115():82-86. PubMed ID: 29432873
[TBL] [Abstract][Full Text] [Related]
5. The presence of circulating tumor cells does not predict extravesical disease in bladder cancer patients prior to radical cystectomy.
Guzzo TJ; McNeil BK; Bivalacqua TJ; Elliott DJ; Sokoll LJ; Schoenberg MP
Urol Oncol; 2012; 30(1):44-8. PubMed ID: 20005748
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
[TBL] [Abstract][Full Text] [Related]
8. Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study.
Rink M; Chun FK; Dahlem R; Soave A; Minner S; Hansen J; Stoupiec M; Coith C; Kluth LA; Ahyai SA; Friedrich MG; Shariat SF; Fisch M; Pantel K; Riethdorf S
Eur Urol; 2012 Apr; 61(4):810-7. PubMed ID: 22277196
[TBL] [Abstract][Full Text] [Related]
9. Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer.
Meyer CP; Pantel K; Tennstedt P; Stroelin P; Schlomm T; Heinzer H; Riethdorf S; Steuber T
Urol Oncol; 2016 May; 34(5):235.e11-6. PubMed ID: 26795608
[TBL] [Abstract][Full Text] [Related]
10. Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer.
Dirix L; Buys A; Oeyen S; Peeters D; Liègeois V; Prové A; Rondas D; Vervoort L; Mariën V; Laere SV; Vermeulen P
Breast Cancer Res Treat; 2022 Jun; 193(2):437-444. PubMed ID: 35397078
[TBL] [Abstract][Full Text] [Related]
11. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W;
BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743
[TBL] [Abstract][Full Text] [Related]
12. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.
Mu Z; Wang C; Ye Z; Austin L; Civan J; Hyslop T; Palazzo JP; Jaslow R; Li B; Myers RE; Jiang J; Xing J; Yang H; Cristofanilli M
Breast Cancer Res Treat; 2015 Dec; 154(3):563-71. PubMed ID: 26573830
[TBL] [Abstract][Full Text] [Related]
13. Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients.
Huebner H; Fasching PA; Gumbrecht W; Jud S; Rauh C; Matzas M; Paulicka P; Friedrich K; Lux MP; Volz B; Gass P; Häberle L; Meier-Stiegen F; Hartkopf A; Neubauer H; Almstedt K; Beckmann MW; Fehm TN; Ruebner M
BMC Cancer; 2018 Feb; 18(1):204. PubMed ID: 29463222
[TBL] [Abstract][Full Text] [Related]
14. Perioperative search for circulating tumor cells in patients undergoing radical cystectomy for bladder cancer.
Karl A; Tritschler S; Hofmann S; Stief CG; Schindlbeck C
Eur J Med Res; 2009 Nov; 14(11):487-90. PubMed ID: 19948444
[TBL] [Abstract][Full Text] [Related]
15. Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.
Sastre J; Maestro ML; Gómez-España A; Rivera F; Valladares M; Massuti B; Benavides M; Gallén M; Marcuello E; Abad A; Arrivi A; Fernández-Martos C; González E; Tabernero JM; Vidaurreta M; Aranda E; Díaz-Rubio E
Oncologist; 2012; 17(7):947-55. PubMed ID: 22643538
[TBL] [Abstract][Full Text] [Related]
16. T1G3 high-risk NMIBC (non-muscle invasive bladder cancer): conservative treatment versus immediate cystectomy.
De Berardinis E; Busetto GM; Antonini G; Giovannone R; Gentile V
Int Urol Nephrol; 2011 Dec; 43(4):1047-57. PubMed ID: 21442469
[TBL] [Abstract][Full Text] [Related]
17. Size-based isolation of circulating tumor cells in lung cancer patients using a microcavity array system.
Hosokawa M; Kenmotsu H; Koh Y; Yoshino T; Yoshikawa T; Naito T; Takahashi T; Murakami H; Nakamura Y; Tsuya A; Shukuya T; Ono A; Akamatsu H; Watanabe R; Ono S; Mori K; Kanbara H; Yamaguchi K; Tanaka T; Matsunaga T; Yamamoto N
PLoS One; 2013; 8(6):e67466. PubMed ID: 23840710
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.
Sastre J; Vidaurreta M; Gómez A; Rivera F; Massutí B; López MR; Abad A; Gallen M; Benavides M; Aranda E; Rubio ED;
Clin Colorectal Cancer; 2013 Dec; 12(4):280-6. PubMed ID: 24012456
[TBL] [Abstract][Full Text] [Related]
19. Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in a United States Population.
Ravvaz K; Walz ME; Weissert JA; Downs TM
J Urol; 2017 Oct; 198(4):824-831. PubMed ID: 28433642
[TBL] [Abstract][Full Text] [Related]
20. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
